Literature DB >> 15060556

The ABCs of artificial antigen presentation.

Jiyun V Kim1, Jean-Baptiste Latouche, Isabelle Rivière, Michel Sadelain.   

Abstract

Artificial antigen presentation aims to accelerate the establishment of therapeutic cellular immunity. Artificial antigen-presenting cells (AAPCs) and their cell-free substitutes are designed to stimulate the expansion and acquisition of optimal therapeutic features of T cells before therapeutic infusion, without the need for autologous antigen-presenting cells. Compelling recent advances include fibroblast AAPCs that process antigens, magnetic beads that are antigen specific, novel T-cell costimulatory combinations, the augmentation of therapeutic potency of adoptively transferred T lymphocytes by interleukin-15, and the safe use of dendritic cell-derived exosomes pulsed with tumor antigen. Whereas the safety and potency of the various systems warrant further preclinical and clinical studies, these emerging technologies are poised to have a major impact on adoptive T-cell therapy and the investigation of T cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15060556     DOI: 10.1038/nbt955

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  52 in total

Review 1.  Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

2.  Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.

Authors:  Naoto Hirano; Marcus O Butler; Zhinan Xia; Sascha Ansén; Michael S von Bergwelt-Baildon; Donna Neuberg; Gordon J Freeman; Lee M Nadler
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

3.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

Review 4.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

5.  T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes.

Authors:  Aura Muntasell; Adam C Berger; Paul A Roche
Journal:  EMBO J       Date:  2007-09-06       Impact factor: 11.598

6.  CARs on track in the clinic.

Authors:  Donald B Kohn; Gianpietro Dotti; Renier Brentjens; Barbara Savoldo; Michael Jensen; Laurence Jn Cooper; Carl H June; Steven Rosenberg; Michel Sadelain; Helen E Heslop
Journal:  Mol Ther       Date:  2011-03       Impact factor: 11.454

Review 7.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).

Authors:  Malarvizhi Durai; Christine Krueger; Zhaohui Ye; Linzhao Cheng; Andreas Mackensen; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Immunol Immunother       Date:  2008-06-18       Impact factor: 6.968

10.  Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.

Authors:  Sascha Ansén; Marcus O Butler; Alla Berezovskaya; Andrew P Murray; Kristen Stevenson; Lee M Nadler; Naoto Hirano
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.